<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092802</url>
  </required_header>
  <id_info>
    <org_study_id>HLX208-BT201</org_study_id>
    <nct_id>NCT05092802</nct_id>
  </id_info>
  <brief_title>The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment</brief_title>
  <official_title>An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Refractory Primary Brain Tumors With BRAF Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of&#xD;
      HLX208 for refractory primary brain tumors with BRAF mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 26, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>from first dose to the last patient was followed up for 6 month</time_frame>
    <description>Objective response rate(assessed by independent radiological review committee (IRRC) based on the RANO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier)，an average of about 1 year</time_frame>
    <description>Progression-free survival(PFS):assessed by IRRC and the investigator based on the RANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first)，an average of about 1 year</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the first dose to the time of death due to any cause，an average of about 2 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Tumor, Primary</condition>
  <arm_group>
    <arm_group_label>HLX208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX208</intervention_name>
    <description>450mg bid po</description>
    <arm_group_label>HLX208</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;=18Y&#xD;
&#xD;
          -  Good Organ Function&#xD;
&#xD;
          -  Expected survival time ≥ 3 months&#xD;
&#xD;
          -  Refractory primary brain tumors with BRAF mutation that have been diagnosed&#xD;
&#xD;
          -  Unable to receive surgery/radiotherapy, or have treatment failed after&#xD;
             surgery/radiotherapy&#xD;
&#xD;
          -  ECOG score 0-1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with BRAF inhibitors or MEK inhibitors&#xD;
&#xD;
          -  A history of other malignancies within two years, except for cured cervical carcinoma&#xD;
             in situ, basal cell carcinoma of the skin, adenocarcinoma in situ of the lung, or&#xD;
             tumors that do not require interventional treatment after radical surgery&#xD;
&#xD;
          -  Severe active infections requiring systemic anti-infective therapy&#xD;
&#xD;
          -  Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation&#xD;
             therapy (except palliative radiation therapy), may be given during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital Affiliated to Shandong first medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinming Yu</last_name>
    <phone>0531-67626819</phone>
    <email>sdyujinming@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhehai Wang</last_name>
    <phone>0531-67626073</phone>
    <email>ywb234@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Shandong first medical University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Yu</last_name>
      <phone>0531-67626819</phone>
      <email>sdyujinming@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

